miR-144在宫颈癌中的研究进展

doi:10.12280/gjfckx.20200940

摘要/Abstract

摘要：

全球范围内,宫颈癌的发病率和死亡率在女性恶性肿瘤中均居于第4位,严重威胁女性的健康,因此早期诊断治疗非常重要。微小RNA（microRNA,miRNA）是一类长度约21~25个核苷酸的非编码内源性小分子RNA,目前大量研究显示miRNA在人体内多种调控途径中具有重要的作用,包括控制细胞的分化、凋亡、增殖以及肿瘤的发生发展,其主要通过与靶mRNA的3′非翻译区（3′-UTR）的碱基结合,从而在转录后水平调控基因的表达发挥其生物学功能。因此,miRNA成为当下肿瘤研究的新热点。目前已有多项研究发现miR-144在许多恶性肿瘤中异常表达,同时也发挥着重要作用。在宫颈癌中,miR-144表达下调,并促进宫颈癌的发生发展,有望成为宫颈癌早期诊断的生物标志物;同时有研究证实miR-144参与调控宫颈癌对放化疗的敏感性,有望成为宫颈癌潜在的治疗靶点。对miR-144的生物学功能及其在宫颈癌中的作用和分子机制作一综述。

关键词: 微小RNA-144, 微RNAs, 宫颈肿瘤, 细胞增殖, 转移侵袭, 生物标记,肿瘤, 抗药性,肿瘤

Abstract:

Globally, the morbidity and mortality of cervical cancer are ranked fourth among female malignancies, seriously threatening women′s health, so early diagnosis and treatment are very important. MicroRNAs (miRNAs) are a class of non coding endogenous small RNAs about 21-25 nucleotides in length, and a large number of studies have now revealed that miRNAs have important roles in multiple regulatory pathways in the human body, including the control of cell differentiation, apoptosis, proliferation as well as tumor development. It exerts its biological functions mainly through base binding to the 3′- untranslated region (3′-UTR) of target mRNAs, thereby regulating the expression of genes at the post transcriptional level. Therefore, miRNAs become a new hotspot in tumor research at the moment. At present, several studies have found that miR-144 is aberrantly expressed in many malignancies and plays an important role as well. In cervical cancer, miR-144 expression is downregulated, and it promotes the occurrence and development of cervical cancer, which is expected to be a biomarker for the early diagnosis of cervical cancer; meanwhile, studies have confirmed that miR-144 is involved in regulating the sensitivity of cervical cancer to chemoradiotherapy, which is expected to be a potential therapeutic target for cervical cancer. In this review, we summarize the biological functions of miR-144 and its roles and molecular mechanisms in cervical cancer.

Key words: MiRNA-144, MicroRNAs, Uterine cervical neoplasms, Cell proliferation, Metastasis and invasion, Biomarkers,tumor, Drug resistance,neoplasm

王君, 俞彩仙, 王侠, 李政. miR-144在宫颈癌中的研究进展[J]. 国际妇产科学杂志, 2021, 48(3): 328-332.

WANG Jun, YU Cai-xian, WANG Xia, LI Zheng. Research Progress of MiR-144 in Cervical Cancer[J]. Journal of International Obstetrics and Gynecology, 2021, 48(3): 328-332.

参考文献 32

[1]	Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis[J]. Lancet Glob Health, 2020,8(2):e191-e203. doi: 10.1016/S2214-109X(19)30482-6. doi: 10.1016/S2214-109X(19)30482-6
[2]	Cohen PA, Jhingran A, Oaknin A, et al. Cervical cancer[J]. Lancet, 2019,393(10167):169-182. doi: 10.1016/S0140-6736(18)32470-X. doi: S0140-6736(18)32470-X pmid: 30638582
[3]	Lu TX, Rothenberg ME. MicroRNA[J]. J Allergy Clin Immunol, 2018,141(4):1202-1207. doi: 10.1016/j.jaci.2017.08.034. doi: 10.1016/j.jaci.2017.08.034
[4]	Asiaf A, Ahmad ST, Arjumand W, et al. MicroRNAs in Breast Cancer: Diagnostic and Therapeutic Potential[J]. Methods Mol Biol, 2018,1699:23-43. doi: 10.1007/978-1-4939-7435-1_2. doi: 10.1007/978-1-4939-7435-1_2
[5]	Yin Y, Cai J, Meng F, et al. MiR-144 suppresses proliferation, invasion, and migration of breast cancer cells through inhibiting CEP55[J]. Cancer Biol Ther, 2018,19(4):306-315. doi: 10.1080/15384047.2017.1416934. doi: 10.1080/15384047.2017.1416934
[6]	Tian QG, Tian RC, Liu Y, et al. The role of miR-144/GSPT1 axis in gastric cancer[J]. Eur Rev Med Pharmacol Sci, 2018,22(13):4138-4145. doi: 10.26355/eurrev_201807_15406. doi: 15406 pmid: 30024602
[7]	Sheng S, Xie L, Wu Y, et al. MiR-144 inhibits growth and metastasis in colon cancer by down-regulating SMAD4[J]. Biosci Rep, 2019, 39(3):BSR20181895. doi: 10.1042/BSR20181895. doi: 10.1042/BSR20181895
[8]	Uchida A, Seki N, Mizuno K, et al. Involvement of dual-strand of the miR-144 duplex and their targets in the pathogenesis of lung squamous cell carcinoma[J]. Cancer Sci, 2019,110(1):420-432. doi: 10.1111/cas.13853. doi: 10.1111/cas.13853
[9]	Kooshkaki O, Rezaei Z, Rahmati M, et al. MiR-144: A New Possible Therapeutic Target and Diagnostic/Prognostic Tool in Cancers[J]. Int J Mol Sci, 2020,21(7):2578. doi: 10.3390/ijms21072578. doi: 10.3390/ijms21072578
[10]	Akiyoshi S, Fukagawa T, Ueo H, et al. Clinical significance of miR-144-ZFX axis in disseminated tumour cells in bone marrow in gastric cancer cases[J]. Br J Cancer, 2012,107(8):1345-1353. doi: 10.1038/bjc.2012.326. doi: 10.1038/bjc.2012.326
[11]	Li J, Sun P, Yue Z, et al. miR-144-3p Induces Cell Cycle Arrest and Apoptosis in Pancreatic Cancer Cells by Targeting Proline-Rich Protein 11 Expression via the Mitogen-Activated Protein Kinase Signaling Pathway[J]. DNA Cell Biol, 2017,36(8):619-626. doi: 10.1089/dna.2017.3656. doi: 10.1089/dna.2017.3656
[12]	Folkman J. Tumor angiogenesis: therapeutic implications[J]. N Engl J Med, 1971,285(21):1182-1186. doi: 10.1056/NEJM197111182852108. doi: 10.1056/NEJM197111182852108
[13]	Matsumoto K, Ema M. Roles of VEGF-A signalling in development, regeneration, and tumours[J]. J Biochem, 2014,156(1):1-10. doi: 10.1093/jb/mvu031. doi: 10.1093/jb/mvu031
[14]	Blanco R, Gerhardt H. VEGF and Notch in tip and stalk cell selection[J]. Cold Spring Harb Perspect Med, 2013,3(1):a006569. doi: 10.1101/cshperspect.a006569. doi: 10.1101/cshperspect.a006569
[15]	Wu M, Huang C, Huang X, et al. MicroRNA-144-3p suppresses tumor growth and angiogenesis by targeting SGK3 in hepatocellular carcinoma[J]. Oncol Rep, 2017,38(4):2173-2181. doi: 10.3892/or.2017.5900. doi: 10.3892/or.2017.5900
[16]	Tao P, Wen H, Yang B, et al. miR-144 inhibits growth and metastasis of cervical cancer cells by targeting VEGFA and VEGFC[J]. Exp Ther Med, 2018,15(1):562-568. doi: 10.3892/etm.2017. 5392. doi: 10.3892/etm.2017. 5392
[17]	Wu J, Zhao Y, Li F, et al. MiR-144-3p: a novel tumor suppressor targeting MAPK6 in cervical cancer[J]. J Physiol Biochem, 2019,75(2):143-152. doi: 10.1007/s13105-019-00681-9. doi: 10.1007/s13105-019-00681-9
[18]	Benedetti Panici P, Basile S, Angioli R. Pelvic and aortic lymphadenectomy in cervical cancer: the standardization of surgical procedure and its clinical impact[J]. Gynecol Oncol, 2009,113(2):284-290. doi: 10.1016/j.ygyno.2008.12.014. doi: 10.1016/j.ygyno.2008.12.014
[19]	Ding H, Wu YL, Wang YX, et al. Characterization of the microRNA expression profile of cervical squamous cell carcinoma metastases[J]. Asian Pac J Cancer Prev, 2014,15(4):1675-1679. doi: 10.7314/apjcp.2014.15.4.1675. doi: 10.7314/apjcp.2014.15.4.1675
[20]	Moon H, Ju HL, Chung SI, et al. Transforming Growth Factor-β Promotes Liver Tumorigenesis in Mice via Up-regulation of Snail[J]. Gastroenterology, 2017, 153(5):1378-1391.e6. doi: 10.1053/j.gastro.2017.07.014. doi: 10.1053/j.gastro.2017.07.014
[21]	Liang F, Ren C, Wang J, et al. The crosstalk between STAT3 and p53/RAS signaling controls cancer cell metastasis and cisplatin resistance via the Slug/MAPK/PI3K/AKT-mediated regulation of EMT and autophagy[J]. Oncogenesis, 2019,8(10):59. doi: 10.1038/s41389-019-0165-8. doi: 10.1038/s41389-019-0165-8 pmid: 31597912
[22]	Savagner P, Yamada KM, Thiery JP. The zinc-finger protein slug causes desmosome dissociation, an initial and necessary step for growth factor-induced epithelial-mesenchymal transition[J]. J Cell Biol, 1997,137(6):1403-1419. doi: 10.1083/jcb.137.6.1403. doi: 10.1083/jcb.137.6.1403 pmid: 9182671
[23]	陈昌贤, 谢雨萱, 莫凌昭, 等. 宫颈癌RNA分子的研究进展[J]. 国际妇产科学杂志, 2018,45(6):634-637. doi: 10.3969/j.issn.1674-1870.2018.06.006. doi: 10.3969/j.issn.1674-1870.2018.06.006
[24]	Zhu Y, Wu Y, Yang L, et al. Long non-coding RNA activated by transforming growth factor-β promotes proliferation and invasion of cervical cancer cells by regulating the miR-144/ITGA6 axis[J]. Exp Physiol, 2019,104(6):837-844. doi: 10.1113/EP087656. doi: 10.1113/EP087656
[25]	Zhang C, Liao Y, Liu P, et al. FABP5 promotes lymph node metastasis in cervical cancer by reprogramming fatty acid metabolism[J]. Theranostics, 2020,10(15):6561-6580. doi: 10.7150/thno.44868. doi: 10.7150/thno.44868
[26]	Shi C, Yang Y, Zhang L, et al. Optimal subset of signature miRNAs consisting of 7 miRNAs that can serve as a novel diagnostic and prognostic predictor for the progression of cervical cancer[J]. Oncol Rep, 2019,41(6):3167-3178. doi: 10.3892/or.2019.7097. doi: 10.3892/or.2019.7097
[27]	Yang C, Ren J, Li B, et al. Identification of clinical tumor stages related mRNAs and miRNAs in cervical squamous cell carcinoma[J]. Pathol Res Pract, 2018,214(10):1638-1647. doi: 10.1016/j.prp.2018.07.035. doi: 10.1016/j.prp.2018.07.035
[28]	Pulati N, Zhang Z, Gulimilamu A, et al. HPV16(+) -miRNAs in cervical cancer and the anti-tumor role played by miR-5701[J]. J Gene Med, 2019,21(11):e3126. doi: 10.1002/jgm.3126. doi: 10.1002/jgm.3126
[29]	Abba ML, Patil N, Leupold JH, et al. MicroRNAs as novel targets and tools in cancer therapy[J]. Cancer Lett, 2017,387:84-94. doi: 10.1016/j.canlet.2016.03.043. doi: 10.1016/j.canlet.2016.03.043
[30]	Shi F, Su J, Liu Z, et al. miR-144 reverses cisplatin resistance in cervical cancer via targeting LHX2[J]. J Cell Biochem, 2019,120(9):15018-15026. doi: 10.1002/jcb.28763. doi: 10.1002/jcb.28763
[31]	Thiery JP. Epithelial-mesenchymal transitions in tumour progression[J]. Nat Rev Cancer, 2002,2(6):442-454. doi: 10.1038/nrc822. doi: 10.1038/nrc822 pmid: 12189386
[32]	Bai M, Che Y, Lu K, et al. Analysis of deubiquitinase OTUD5 as a biomarker and therapeutic target for cervical cancer by bioinformatic analysis[J]. Peer J, 2020,8:e9146. doi: 10.7717/peerj.9146. doi: 10.7717/peerj.9146